VAN: Effect of NMN Supplementation on Organ System Biology
Study Details
Study Description
Brief Summary
The goal of this proposal is to determine whether the beneficial effects of NMN on metabolic function observed in rodents applies to people.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
This study is looking at the effect of the dietary supplement "Nicotinamide mononucleotide" (NMN) on key cardiovascular and metabolic functions, specifically those that are important risk factors for diabetes and cardiovascular disease.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Placebo Comparator: Placebo At least 16 weeks of placebo. |
Other: Placebo
Intervention will last at least 16 weeks in the form of two capsules.
|
| Experimental: NMN supplementation At least 16 weeks of NMN. |
Dietary Supplement: Treatment
Intervention will last at least 16 weeks in the form of two NMN capsules (total of 300 mg/day).
|
Outcome Measures
Primary Outcome Measures
- Change in Muscle insulin sensitivity [before and after at least 16 weeks of treatment]
The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period.
Secondary Outcome Measures
- Changes in glucose tolerance [before and after at least 16 weeks of treatment]
The outcome will be assessed during modified oral glucose tolerance test
Eligibility Criteria
Criteria
Inclusion Criteria:
-
BMI 25.0-34.9 kg/m²
-
Prediabetes defined as a 2-h oral glucose tolerance test plasma glucose of 140-199 mg/dL with or without a fasting plasma glucose of 100-125 mg/dL, or HbA1C ≥5.7.
Exclusion Criteria:
-
Women who are still having menses
-
Persons who take niacin, nicotinamide, or other vitamin B3-related supplementation and are not willing to discontinue supplementation for 3 weeks before medical screening and during the entire study period
-
Persons who consume moderate-large amounts of caffeine daily (>2 cups of coffee or 8 oz caffeinated drinks per day) or consume less amounts of caffeine but believe withdrawal symptoms (e.g. headache) are likely if caffeine is stopped
-
Unstable weight (>3% change during the last 2 months before entering the study)
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
Sponsors and Collaborators
- Washington University School of Medicine
- United States Department of Defense
Investigators
- Principal Investigator: Samuel Klein, MD, Washington University School of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 201909118